Klotho‑PP2A Axis Tunes BCL‑2/Beclin‑1 Binding to Confer Tissue‑Specific Autophagy Activation in Aging

Hypothesis

The anti‑aging protein Klotho does not merely correlate with reduced BCL‑2/Beclin‑1 binding; it actively promotes dephosphorylation of BCL‑2 at serine‑70 (or a comparable regulatory site) via recruitment of the phosphatase PP2A, thereby weakening the BCL‑2/Beclin‑1 interaction in a tissue‑specific manner. In heart and kidney, where Klotho expression is high, this dephosphorylation shifts the equilibrium toward free Beclin‑1, stimulating autophagosome formation. In liver, low Klotho levels and dominant opposing kinases (e.g., mTORC1‑S6K) maintain BCL‑2 phosphorylation, preserving the inhibitory complex despite systemic Klotho elevation.

Mechanistic model

1. Klotho binds to BCL‑2 through its extracellular domain, presenting an intracellular motif that attracts PP2A.
2. PP2A dephosphorylates BCL‑2 at a BH3‑adjacent serine, reducing its affinity for Beclin‑1’s BH3 groove.
3. Dephosphorylated BCL‑2 releases Beclin‑1, allowing Vps34 complex assembly and increased autophagy.
4. In tissues lacking sufficient Klotho or PP2A activity (e.g., liver), BCL‑2 remains phosphorylated, maintaining autophagy suppression.

Predictions

• Acute Klotho supplementation will increase LC3‑II turnover (with bafilomycin A1) in heart and kidney of aged wild‑type mice but not in liver.
• Co‑administration of a low‑dose PP2A inhibitor (e.g., okadaic acid at 1 nM) will abolish the Klotho‑induced autophagy increase in heart/kidney without affecting apoptosis.
• In F121A Beclin‑1 knock‑in mice, Klotho treatment will produce no further autophagy enhancement in heart/kidney because the BCL‑2/Beclin‑1 interaction is already disrupted.
• Liver autophagy will remain unchanged across all conditions unless PP2A is artificially overexpressed alongside Klotho.

Experimental approach

• Use 20‑month‑old wild‑type and F121A mice; treat groups with recombinant Klotho, Klotho + PP2A inhibitor, or vehicle for 2 weeks.
• Measure autophagy flux via LC3‑II/I ratio and p62 levels after lysosomal blockade, assess BCL‑2 phosphorylation by phospho‑specific western blot, and quantify PP2A activity immunoprecipitated from tissue lysates.
• Validate tissue specificity by histology (fibrosis, hypertrophy) and functional assays (echocardiography, creatinine clearance).

If Klotho‑dependent PP2A recruitment drives tissue‑selective BCL‑2/Beclin‑1 dissociation, this hypothesis explains why systemic Klotho elevation rescues Klotho‑deficient phenotypes yet yields muted effects in liver, and it points to PP2A as a co‑target for enhancing autophagy‑based therapeutics without broadly disrupting BCL‑2’s anti‑apoptotic functions.